Market Snapshot

S&P Futures
4,401.75
Dow Futures
34,931.00
NASDAQ Futures
15,099.25

3.24$-0.14 -4.14%
Market open    14:49:46 pm   
From: To:

Stock Snapshot

3.38
Prev. Close
3.25
Open
72.51M
Market Cap
359300.00
Number of Shares
3.1650
Day Low
3.5400
Day High
3.24
-
P/E Ratio
6.34M
Free Float in %
-1.67
EPS 2021
0.61
Book Value per Share
0.58
Cash Flow per Share
NeuroBo Pharmaceuticals, Inc. (NRBO)
NeuroBo Pharmaceuticals, Inc. (NRBO) stock rallied over -4.14% intraday to trade at $3.24 per share on NASDAQ. The stock opened with a fall of -3.85% at $3.25 and touched an intraday high of $3.5400, rising 4.73% against the last close of $3.38. The stock went to a low of $3.1650 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-06-30$3.22$3.33$3.33$3.39$3.11256,822
2021-06-29$3.44$3.26$3.26$3.44$3.17233,800
2021-06-28$3.31$3.34$3.34$3.46$3.23194,200
2021-06-25$3.15$3.25$3.25$3.30$3.10788,600
2021-06-24$3.15$3.20$3.20$3.25$3.07244,900
2021-06-23$3.01$3.21$3.21$3.23$3.01186,700
2021-06-22$3.03$2.96$2.96$3.25$2.95414,600
2021-06-21$3.26$3.03$3.03$3.35$3.03339,400
2021-06-18$3.51$3.27$3.27$3.58$3.27300,500
2021-06-17$3.26$3.56$3.56$3.67$3.26408,100
2021-06-16$3.26$3.23$3.23$3.40$3.05549,800
NeuroBo Pharmaceuticals, Inc.
200 Berkeley Street
19th Floor
Boston, MA 02116
United States

http://www.neurobopharma.com
857 702 9600
Employees
12
Sector
Healthcare
Sales or Revenue
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30
Dr. Jeong Gu Kang Ph.D.
Pres, CEO, Sec., Interim CFO, Treasurer & Director
Mr. Akash Bakshi
COO, Sr. VP & Director
NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam